NCT01723020View on ClinicalTrials.gov

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

December 27, 2012

Primary Completion Date

March 15, 2017

Study Completion Date

September 25, 2017

Conditions
Advanced MalignancyAdvanced Solid TumorsCancerOncologyOncology PatientsTumorsGlioblastomaMultiple Myeloma
Interventions
DRUG

AMG 232

Given an an oral tablet in escalating doses.

Trial Locations (14)

10021

Research Site, New York

29605

Greenville Hospital System, Greenville

Research Site, Greenville

69373

Research Site, Lyon

90403

Research Site, Santa Monica

94805

Research Site, Villejuif

06856

Research Site, Norwalk

02115

Research Site, Boston

02215

Research Site, Boston

07601

Research Site, Hackensack

08901

Research Site, New Brunswick

1066 CX

Research Site, Amsterdam

3015 CE

Research Site, Rotterdam

3584 CX

Research Site, Utrecht

Sponsors
All Listed Sponsors
lead

Kartos Therapeutics, Inc.

INDUSTRY

NCT01723020 - A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | Biotech Hunter | Biotech Hunter